These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 28872367)

  • 21. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.
    Roukos DH; Tzakos A; Zografos G
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1413-6. PubMed ID: 19828000
    [No Abstract]   [Full Text] [Related]  

  • 22. Vascular disrupting agents (VDAs) in anticancer therapy.
    Daenen LG; Roodhart JM; Shaked Y; Voest EE
    Curr Clin Pharmacol; 2010 Aug; 5(3):178-85. PubMed ID: 20406172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Rationale of antiangiogenic therapy].
    Tímár J; Paku S; Tóvári J; Döme B
    Magy Onkol; 2006; 50(2):141-51. PubMed ID: 16888678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metformin and Angiogenesis in Cancer - Revisited.
    Kannarkatt J; Alkharabsheh O; Tokala H; Dimitrov NV
    Oncology; 2016; 91(4):179-184. PubMed ID: 27487294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vascular disrupting agents (VDA) in oncology: advancing towards new therapeutic paradigms in the clinic.
    Spear MA; LoRusso P; Mita A; Mita M
    Curr Drug Targets; 2011 Dec; 12(14):2009-15. PubMed ID: 21777190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?
    Kerbel RS
    Science; 2006 May; 312(5777):1171-5. PubMed ID: 16728631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TEM8 targeted cancer therapy.
    Frankel AE; Carter C; Kuo SR; Woo JH; Mauldin J; Liu JS
    Anticancer Agents Med Chem; 2011 Dec; 11(10):983-92. PubMed ID: 22023048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
    Leite de Oliveira R; Hamm A; Mazzone M
    Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor angiogenesis and vascular normalization: alternative therapeutic targets.
    Viallard C; Larrivée B
    Angiogenesis; 2017 Nov; 20(4):409-426. PubMed ID: 28660302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microenvironment-Mediated Modeling of Tumor Response to Vascular-Targeting Drugs.
    Gevertz JL
    Adv Exp Med Biol; 2016; 936():191-208. PubMed ID: 27739049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advanced Chemoembolization by Anti-angiogenic Calcium-Phosphate Ceramic Microspheres Targeting the Vascular Heterogeneity of Cancer Xenografts.
    Emoto M; Yoshihisa H; Yano K; Choijamts B; Tsugu H; Tachibana K; Aizawa M
    Anticancer Res; 2015 Sep; 35(9):4757-64. PubMed ID: 26254366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies.
    Kanthou C; Tozer GM
    Int J Exp Pathol; 2009 Jun; 90(3):284-94. PubMed ID: 19563611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-angiogenic therapies in cancer: achievements and open questions.
    Ruegg C; Mutter N
    Bull Cancer; 2007 Sep; 94(9):753-62. PubMed ID: 17878094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
    Jain RK
    Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics.
    Fuso Nerini I; Cesca M; Bizzaro F; Giavazzi R
    Chin J Cancer; 2016 Jun; 35(1):61. PubMed ID: 27357621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-angiogenesis in neuroblastoma.
    Ribatti D
    Crit Rev Oncol Hematol; 2013 Jun; 86(3):212-21. PubMed ID: 23273512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential role of vascular targeted therapy to combat against tumor.
    Chen B; Jin H; Wu K
    Expert Opin Drug Deliv; 2009 Jul; 6(7):719-26. PubMed ID: 19538038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-vascular nano agents: a promising approach for cancer treatment.
    Chen D; Qu X; Shao J; Wang W; Dong X
    J Mater Chem B; 2020 Apr; 8(15):2990-3004. PubMed ID: 32211649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiangiogenic and vascular-disrupting agents in endometriosis: pitfalls and promises.
    Van Langendonckt A; Donnez J; Defrère S; Dunselman GA; Groothuis PG
    Mol Hum Reprod; 2008 May; 14(5):259-68. PubMed ID: 18430758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.